Literature DB >> 8381360

Mediation by nitric oxide of neurally-induced human cerebral artery relaxation.

N Toda1.   

Abstract

Human cerebral artery strips relaxed in response to non-adrenergic, non-cholinergic vasodilator nerve stimulation by electrical pulses or nicotine. The relaxation response was abolished by treatment with NG-nitro-L-arginine, a nitric oxide synthase inhibitor; the inhibitory effect was reversed by L-, but not D-, arginine. Nitric oxide-induced relaxation was unaffected. These findings support the hypothesis that nitric oxide plays a crucial role, possibly as neurotransmitter, in transmitting information from vasodilator nerve to smooth muscle in human cerebral arteries.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381360     DOI: 10.1007/bf01928789

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  12 in total

1.  Nicotine-induced relaxation in isolated canine cerebral arteries.

Authors:  N Toda
Journal:  J Pharmacol Exp Ther       Date:  1975-05       Impact factor: 4.030

2.  Inhibitory effects of L-NG-nitro-arginine on the synthesis of EDRF and the cerebroarterial response to vasodilator nerve stimulation.

Authors:  N Toda; Y Minami; T Okamura
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

3.  Possible role of nitric oxide in transmitting information from vasodilator nerve to cerebroarterial muscle.

Authors:  N Toda; T Okamura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-16       Impact factor: 3.575

4.  Mechanism underlying the response to vasodilator nerve stimulation in isolated dog and monkey cerebral arteries.

Authors:  N Toda; T Okamura
Journal:  Am J Physiol       Date:  1990-11

5.  Localization of nitric oxide synthase indicating a neural role for nitric oxide.

Authors:  D S Bredt; P M Hwang; S H Snyder
Journal:  Nature       Date:  1990-10-25       Impact factor: 49.962

6.  Relaxant responses to transmural stimulation and nicotine of dog and monkey cerebral arteries.

Authors:  N Toda
Journal:  Am J Physiol       Date:  1982-08

7.  Cholinergic prejunctional inhibition of vasodilator nerve function in bovine basilar arteries.

Authors:  N Toda; K Ayajiki
Journal:  Am J Physiol       Date:  1990-04

8.  L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro.

Authors:  P K Moore; O A al-Swayeh; N W Chong; R A Evans; A Gibson
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

9.  Non-adrenergic, non-cholinergic innervation in monkey and human cerebral arteries.

Authors:  N Toda
Journal:  Br J Pharmacol       Date:  1981-02       Impact factor: 8.739

10.  Postmortem functional changes in coronary and cerebral arteries from humans and monkeys.

Authors:  N Toda; T Okamura; I Shimizu; Y Tatsuno
Journal:  Cardiovasc Res       Date:  1985-11       Impact factor: 10.787

View more
  5 in total

1.  Endothelial function and white matter hyperintensities in older adults with cardiovascular disease.

Authors:  Karin F Hoth; David F Tate; Athena Poppas; Daniel E Forman; John Gunstad; David J Moser; Robert H Paul; Angela L Jefferson; Andreana P Haley; Ronald A Cohen
Journal:  Stroke       Date:  2007-01-04       Impact factor: 7.914

2.  Inhibition of nitroxidergic nerve function by neurogenic acetylcholine in monkey cerebral arteries.

Authors:  N Toda; K Ayajiki; T Okamura
Journal:  J Physiol       Date:  1997-01-15       Impact factor: 5.182

3.  Localisation of immunoreactive factor VIII, nitric oxide synthase, substance P, endothelin-1 and 5-hydroxytryptamine in human postmortem middle cerebral artery.

Authors:  E Gorelova; A Loesch; P Bodin; L Chadwick; P J Hamlyn; G Burnstock
Journal:  J Anat       Date:  1996-02       Impact factor: 2.610

Review 4.  Recent advances in research on nitrergic nerve-mediated vasodilatation.

Authors:  Noboru Toda; Tomio Okamura
Journal:  Pflugers Arch       Date:  2014-10-23       Impact factor: 3.657

Review 5.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.